319 related articles for article (PubMed ID: 27073265)
1. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
Wu CK; Chang KC; Hung CH; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hu TH
J Antimicrob Chemother; 2016 Jul; 71(7):1943-7. PubMed ID: 27073265
[TBL] [Abstract][Full Text] [Related]
2. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
[TBL] [Abstract][Full Text] [Related]
3. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
5. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
[TBL] [Abstract][Full Text] [Related]
6. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
[TBL] [Abstract][Full Text] [Related]
9. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
10. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
11. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Chen TM; Lin CC; Huang PT; Wen CF
Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
[TBL] [Abstract][Full Text] [Related]
12. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
13. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
14. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
15. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
[TBL] [Abstract][Full Text] [Related]
16. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
17. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
18. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
20. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]